Treatments

Treatment Delays in T2D Increase Cardiovascular Biomarkers

Treatment Delays in T2D Increase Cardiovascular Biomarkers

Serum NT-proBNP and serum hsTnl levels were examined at baseline, 26, 52, and 104 weeks.

Ipragliflozin vs Pioglitazone for NAFLD in T2D

Ipragliflozin vs Pioglitazone for NAFLD in T2D

Ipragliflozin showed "equally beneficial effects" on glycemic control in patients with nonalcoholic fatty liver disease and type 2 diabetes.

GSK Announces Discontinuation of Injectable Therapy for T2D

GSK Announces Discontinuation of Injectable Therapy for T2D

By

GlaxoSmithKline expects Tanzeum supplies to be depleted by July 2018.

FDA: Liraglutide Approved for MACE in T2D With Established CVD

FDA: Liraglutide Approved for MACE in T2D With Established CVD

By

Approval for the new indication follows a review of the results of the LEADER trial.

Painful Diabetic Neuropathy: Challenges in Symptom Relief

Painful Diabetic Neuropathy: Challenges in Symptom Relief

A phase 2 clinical trial examined the efficacy of treating painful diabetic neuropathy (PDN) with filorexant, an orexin receptor antagonist.

Comparative Risk of Bladder Cancer With Pioglitazone vs DPP-4s, Sulfonylureas

Comparative Risk of Bladder Cancer With Pioglitazone vs DPP-4s, Sulfonylureas

By

Pioglitazone in comparison to dipeptidyl-peptidase-4 inhibitors and sulfonylureas, is associated with an increased risk for bladder cancer.

Lusduna Nexvue Follow-On Biologic Tentatively Approved by FDA

Lusduna Nexvue Follow-On Biologic Tentatively Approved by FDA

By

Tentative FDA approval has been granted to Merck's follow-on biologic basal insulin injection.

Sign Up for Free e-Newsletters